All News
Clinical pearl! Talk to your PsA pts about sleep. Abs 0387 shows circular relationship between sleep quality, emotional disorders, and activity in these patients. Emotional factors more relevant than inflammatory factors on sleep quality. #ACR22 @RheumNow https://t.co/0p5hfNHM91 https://t.co/XrMTmsoMYR
Dr. Rachel Tate uptoTate ( View Tweet)
Patel @NaomiRheumMD et al. Baseline GTI in GCA in GiACTA. Blood pressure and glucose tolerance biggest contributors. Higher in relapsing 122.5 vs 98.9. BMI and neuropsych higher in relapsing. @rheumnow #ACR22 Abstr#0460 https://t.co/dSIt1xEOva https://t.co/2tAkgVEEeA
Richard Conway RichardPAConway ( View Tweet)
Patel @NaomiRheumMD et al. HbA1c in GiACTA. Tocilizumab assoc HbA1c reduction independent of steroids. Daily steroid dose assoc HbA1c @rheumnow #ACR22 Abstr#0461 https://t.co/9Nbewrpww8 https://t.co/NyeTyWICF6
Richard Conway RichardPAConway ( View Tweet)
Clinical pearl! Patient-reported treatment success in PsA assoc'd w/ control of arthritis, dactylitis, psoriasis, and health-related QoL. Top 3 pt-reported reasons for tx failure were pain, psoriasis and fatigue. Abs0393 #ACR22 @RheumNow https://t.co/F9RNI7EXcL https://t.co/7DcLaqUqnm
Dr. Rachel Tate uptoTate ( View Tweet)
Smith et al. MMF equally good if not better for Black vs White patients with SSc-ILD. Suggests worse outcomes for Black patients relate to more severe disease at presentation rather than treatment failure @RheumNow #ACR22 Abstr#0521 https://t.co/xZtAt6Kw1f https://t.co/f0jG9jsgQ7
Richard Conway RichardPAConway ( View Tweet)
Fukui et al. Retrospective study of alternate day steroids in IgG4-RD. No difference in flares. Significantly lower Glucocorticoid toxicity index -29.5 at 12 months -20 at 24 months. Not convinced until I see stronger data! @rheumnow #ACR22 Abstr#0128 https://t.co/20K4dKXE7R https://t.co/X4kJgCqhAE
Richard Conway RichardPAConway ( View Tweet)
Maguire et al @Sineadm15 @bososhea Stronger relationship between disease activity and QoL in men than women with AxSpA. Our current tools may be inadequate to fully evaluate women with AxSpA @rheumnow #ACR22 Abstr#0406 https://t.co/duHqO0DXh3 https://t.co/yRcFiNpujT
Richard Conway RichardPAConway ( View Tweet)
Woody Palmer fasciitis? Think cancer (esp ovarian CA in women) #acr22 @rheumnow https://t.co/c6nCATfGxt
TheDaoIndex KDAO2011 ( View Tweet)
Tofactinib efficacy for treatment of ankylosing spondylitis comparable across different BMI's. Regardless of BMI, tofacitinib better than placebo.
BMI <25: more AE and SAE
Abs#0405 @RheumNow #ACR22 https://t.co/qs3U4mjUXD
Robert B Chao, MD doctorRBC ( View Tweet)
Rates of MACE and VTE with upadacitinib were infrequent and consistent with background rates in RA, PsA and AS patients. Factors associated with MACE/VTE: age>65, HTN, DM, smoking, history CV event/VTE
Abs#0510 @RheumNow #ACR22 https://t.co/AjtJF0p3QK
Robert B Chao, MD doctorRBC ( View Tweet)
Do you consider ttmt successful? Question Christeen et al. asked to 100+ PsA pts. 1/3 pts said no, they had > TJC, > SJC, > Pso & > dactylitis.
Failure also w/: pain 24%, pso 15%, fatigue 12% and < ability to be active 9%.
https://t.co/dQseCNSDBS Abstr #0393 #ACR22 @Rheumnow https://t.co/kGlmscsKL7
Aurelie Najm AurelieRheumo ( View Tweet)
MACE and VTE from 9 (6 RA, 2 PsA, 1 AS) RCTs w/ UPA.
6000+ pts received UPA 40-50% w/ > or = 2 BL CV risk factors.
41 MACE UPA 15mg RA-PsA group & 2 fatal VTE UPA 15mg RA group.
Overlapping confidence intervals w/ADA & MTX.
https://t.co/7xtZlDIkVu
Abs#0510 #ACR22 @Rheumnow https://t.co/reywXk5Z0Z
Aurelie Najm AurelieRheumo ( View Tweet)
RECITAL trial comparing ritux vs cyclo for CTD-ILD. This is a sub-group analysis of larger trial. 1/n
@RheumNow #ACR22 #Plenary
Julian Segan JulianSegan ( View Tweet)
GPA is a rare cause of both submandibular gland enlargement and dacryoadenitis. Can look like IgG4RD and Sjogrens.
@RheumNow #ACR22 #Pearls https://t.co/Gw6OF4H2w2
Julian Segan JulianSegan ( View Tweet)
Are my patients represented in PsA trials? @RheumNow #ACR22
Abstract #0090; Ignite Talk
☝️Of 25 RCT from 2002-2022, only 13 included patients of non-White race
☝️Hispanic/Latinx ethnicity was reported in 0 studies
☝️Black individuals represented < 1% patients included
Catherine Sims, MD DrCassySims ( View Tweet)
Dr. John Stone pronounces GiACTA “GEE-ACTA”. I have been pronouncing it “GIA-ACTA” and will now correct myself #vasculitis #ACR22
Catherine Sims, MD DrCassySims ( View Tweet)
#ACR22 Year in Review. Dr Langford summarised significant progress attained in 2022 in combating #COVID and protect our immunosuppressed patients @RheumNow https://t.co/lZSDRj3bkm
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Key points in managing MDA5+ DM
1. Monitor lungs - HRCT/PFTs
2. Test muscle endurance (ref: IMACS site) not just strength
3. Close observation
4. MTX/MMF initial treatments
5. Repeat muscle biopsy if diagnosis unclear
Meet the Expert Lundberg I, IMM session @RheumNow #ACR22 https://t.co/ZVFsYgDBx2
Dr. Antoni Chan synovialjoints ( View Tweet)
Key points in managing MDA5+ DM
1. Consider Tofacitinib 5-10mg bd
2. Low to mid dose Prednisolone 20-30mg tapering
3. Other Rx: Tacrolimus, IVIG
4. Poor prognostic factors: lymphopenia, raised ferritin, old age, rapid ILD progression
Wang GC, IIM session @RheumNow #ACR22 https://t.co/UF2PjAg0Mw
Dr. Antoni Chan synovialjoints ( View Tweet)
Therapies for AS and nr-AxSpA are coming together. Both AS and nr-AxSpA present with similar burden of disease. TNFi, IL-17i and JAKi now approved for use in nr-AxSpA.
Jose U Scher, SpA Review @RheumNow #ACR22 https://t.co/vcHcd7OyAU
Dr. Antoni Chan synovialjoints ( View Tweet)